Abstract
We examined the prevent effect of a whey hydrolyzed formula (NAN H.A.) on the development of allergic disease from new born infants. A hundred thirty three pregnant women were divided into the NAN H.A. group and the control group. Mothers, who agreed to use the whey hydrolyzed formula to their infant, were classified into the NAN H.A. group. We examined laboratory date such as IgE levels of these infants as well as clinical symptoms for evaluating of the preventive effect of NAN H.A. The serum IgE levels from infants of the NAN H.A. group were lower than those of the control group. The incidance of the infants who showed allergic clinical symptoms was significant lower in the NAN H.A. group. The odds ratio to skin symptom at 3 years of age with muItiple logistic regression was 5.32 between the control group and the NAN H.A. group (p<0.05). It was 6.68 between mother's history of allergy was positive and negative (p<0.02). These results suggest that NAN H.A. can prevent the development of allergic symptoms in infants.
